Brief: Medincell Says Phase 3 Data Shows No PDSS In Olanzapine LAI
22/09/2025 06:33
Sept 22 (Reuters) - Medincell SA MEDCL.PA: PHASE 3 DATA SHOWS NO PDSS IN OLANZAPINE LAI TEVA PLANS NDA SUBMISSION FOR OLANZAPINE LAI IN US Q4 2025 Source text: ID:nBw9zSbTxa Further company coverage: MEDCL.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris